Current Report Filing (8-k)
October 31 2016 - 8:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event
Reported): October 26, 2016
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
|
|
|
18th Floor, Jialong International Building
|
19 Chaoyang Park Road
|
Chaoyang District, Beijing 100125
|
People’s Republic of China
|
(Address of Principal Executive Offices)
86-10-6598-3111
Registrant's telephone number, including
area code
____________________________________________________________
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
ITEM 8.01. OTHER EVENTS.
On October 26, 2016, China Biologic Products, Inc. (the “Company”)
issued a press release announcing that Guizhou Taibang Biological Products Co. Ltd. (“Guizhou Taibang”) completed the
requisite legal and administrative procedures, through which two former minority shareholders, holding a combined 15.3% equity
interest in Guizhou Taibang, withdrew their respective capital contributions in Guizhou Taibang for an aggregate consideration
of RMB415.0 million (approximately US$62.1 million) pursuant to an agreement dated July 31, 2016, a summary English translation
of which was filed as an exhibit to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission
on August 4, 2016. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by
reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
The list of exhibits in the
Exhibit Index to this report is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 31, 2016
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
|
|
By:
|
|
/s/ David (Xiaoying) Gao
|
|
|
|
|
David (Xiaoying) Gao
|
|
|
|
|
Chief Executive Officer
|
|
Exhibit Index
Exhibit Number
|
Description
|
99.1
|
Press Release issued by the Company dated October 26, 2016
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024